Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy

January 27th, 2022

The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).

Now let us dig a bit more into those headlines.

CardsJC: EMPEROR-Preserved Trial - Cardionerds Twitter Journal Club

 

Share | Download(Loading)
Podbean App

Play this podcast on Podbean App